KCM
VTVT icon

Kennedy Capital Management’s vTv Therapeutics VTVT Stock Holding History

Kennedy Capital Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,353
Closed -$314K – 752
2016
Q2 		$314K Sell
1,353
-12
-0.9% -$2.76K 0.01% 686
2016
Q1 		$282K Buy
+1,365
New +$340K 0.01% 712

Other funds holding VTVT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $135M AUM 0.15% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Kennedy Capital Management's VTVT Position: Q3 2016 in Review

Kennedy Capital Management sold out of vTv Therapeutics (VTVT) in Q3 2016, closing a stake of 1,353 shares — an estimated $314K sold.

Kennedy Capital Management first reported a position in VTVT in Q1 2016 and held it in 2 quarters. The position peaked at $314K in Q2 2016. 36 funds tracked by Wall St. Rank hold VTVT as of Q3 2016.

  • Kennedy Capital Management reported no remaining vTv Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Kennedy Capital Management sold 1,353 vTv Therapeutics shares in Q3 2016, an estimated $314K.
  • Kennedy Capital Management first reported a position in vTv Therapeutics in Q1 2016 and held it in 2 quarters.
  • Kennedy Capital Management's vTv Therapeutics position peaked at $314K in Q2 2016.
  • 36 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2016.

Based on Kennedy Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.